Cargando…
Reduction of neutrophilic lung inflammation by inhalation of the compatible solute ectoine: a randomized trial with elderly individuals
BACKGROUND: Compatible solutes are natural substances that are known to stabilize cellular functions. Preliminary ex vivo and in vivo studies demonstrated that the compatible solute ectoine restores natural apoptosis rates of lung neutrophils and contributes to the resolution of lung inflammation. D...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5076798/ https://www.ncbi.nlm.nih.gov/pubmed/27799756 http://dx.doi.org/10.2147/COPD.S115061 |
_version_ | 1782462087334723584 |
---|---|
author | Unfried, Klaus Krämer, Ursula Sydlik, Ulrich Autengruber, Andrea Bilstein, Andreas Stolz, Sabine Marini, Alessandra Schikowski, Tamara Keymel, Stefanie Krutmann, Jean |
author_facet | Unfried, Klaus Krämer, Ursula Sydlik, Ulrich Autengruber, Andrea Bilstein, Andreas Stolz, Sabine Marini, Alessandra Schikowski, Tamara Keymel, Stefanie Krutmann, Jean |
author_sort | Unfried, Klaus |
collection | PubMed |
description | BACKGROUND: Compatible solutes are natural substances that are known to stabilize cellular functions. Preliminary ex vivo and in vivo studies demonstrated that the compatible solute ectoine restores natural apoptosis rates of lung neutrophils and contributes to the resolution of lung inflammation. Due to the low toxicity and known compatibility of the substance, an inhalative application as an intervention strategy for humans suffering from diseases caused by neutrophilic inflammation, like COPD, had been suggested. As a first approach to test the feasibility and efficacy of such a treatment, we performed a population-based randomized trial. OBJECTIVE: The objective of the study was to test whether the daily inhalation of the registered ectoine-containing medical device (Ectoin(®) inhalation solution) leads to a reduction of neutrophilic cells and interleukin-8 (IL-8) levels in the sputum of persons with mild symptoms of airway disease due to lifelong exposure to environmental air pollution. METHODS: A double-blinded placebo-controlled trial was performed to study the efficacy and safety of an ectoine-containing therapeutic. Prior to and after both inhalation periods, lung function, inflammatory parameters in sputum, serum markers, and quality-of-life parameters were determined. RESULTS: While the other outcomes revealed no significant effects, sputum parameters were changed by the intervention. Nitrogen oxides (nitrate and nitrite) were significantly reduced after ectoine inhalation with a mean quotient of 0.65 (95% confidence interval 0.45–0.93). Extended analyses considering period effects revealed that the percentage of neutrophils in sputum was significantly lower after ectoine inhalation than in the placebo group (P=0.035) even after the washout phase. CONCLUSION: The current study is the first human trial in which the effects of inhaled ectoine on neutrophilic lung inflammation were investigated. Besides demonstrating beneficial effects on inflammatory sputum parameters, the study proves the feasibility of the therapeutic approach in an aged study group. |
format | Online Article Text |
id | pubmed-5076798 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Dove Medical Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-50767982016-10-31 Reduction of neutrophilic lung inflammation by inhalation of the compatible solute ectoine: a randomized trial with elderly individuals Unfried, Klaus Krämer, Ursula Sydlik, Ulrich Autengruber, Andrea Bilstein, Andreas Stolz, Sabine Marini, Alessandra Schikowski, Tamara Keymel, Stefanie Krutmann, Jean Int J Chron Obstruct Pulmon Dis Original Research BACKGROUND: Compatible solutes are natural substances that are known to stabilize cellular functions. Preliminary ex vivo and in vivo studies demonstrated that the compatible solute ectoine restores natural apoptosis rates of lung neutrophils and contributes to the resolution of lung inflammation. Due to the low toxicity and known compatibility of the substance, an inhalative application as an intervention strategy for humans suffering from diseases caused by neutrophilic inflammation, like COPD, had been suggested. As a first approach to test the feasibility and efficacy of such a treatment, we performed a population-based randomized trial. OBJECTIVE: The objective of the study was to test whether the daily inhalation of the registered ectoine-containing medical device (Ectoin(®) inhalation solution) leads to a reduction of neutrophilic cells and interleukin-8 (IL-8) levels in the sputum of persons with mild symptoms of airway disease due to lifelong exposure to environmental air pollution. METHODS: A double-blinded placebo-controlled trial was performed to study the efficacy and safety of an ectoine-containing therapeutic. Prior to and after both inhalation periods, lung function, inflammatory parameters in sputum, serum markers, and quality-of-life parameters were determined. RESULTS: While the other outcomes revealed no significant effects, sputum parameters were changed by the intervention. Nitrogen oxides (nitrate and nitrite) were significantly reduced after ectoine inhalation with a mean quotient of 0.65 (95% confidence interval 0.45–0.93). Extended analyses considering period effects revealed that the percentage of neutrophils in sputum was significantly lower after ectoine inhalation than in the placebo group (P=0.035) even after the washout phase. CONCLUSION: The current study is the first human trial in which the effects of inhaled ectoine on neutrophilic lung inflammation were investigated. Besides demonstrating beneficial effects on inflammatory sputum parameters, the study proves the feasibility of the therapeutic approach in an aged study group. Dove Medical Press 2016-10-18 /pmc/articles/PMC5076798/ /pubmed/27799756 http://dx.doi.org/10.2147/COPD.S115061 Text en © 2016 Unfried et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. |
spellingShingle | Original Research Unfried, Klaus Krämer, Ursula Sydlik, Ulrich Autengruber, Andrea Bilstein, Andreas Stolz, Sabine Marini, Alessandra Schikowski, Tamara Keymel, Stefanie Krutmann, Jean Reduction of neutrophilic lung inflammation by inhalation of the compatible solute ectoine: a randomized trial with elderly individuals |
title | Reduction of neutrophilic lung inflammation by inhalation of the compatible solute ectoine: a randomized trial with elderly individuals |
title_full | Reduction of neutrophilic lung inflammation by inhalation of the compatible solute ectoine: a randomized trial with elderly individuals |
title_fullStr | Reduction of neutrophilic lung inflammation by inhalation of the compatible solute ectoine: a randomized trial with elderly individuals |
title_full_unstemmed | Reduction of neutrophilic lung inflammation by inhalation of the compatible solute ectoine: a randomized trial with elderly individuals |
title_short | Reduction of neutrophilic lung inflammation by inhalation of the compatible solute ectoine: a randomized trial with elderly individuals |
title_sort | reduction of neutrophilic lung inflammation by inhalation of the compatible solute ectoine: a randomized trial with elderly individuals |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5076798/ https://www.ncbi.nlm.nih.gov/pubmed/27799756 http://dx.doi.org/10.2147/COPD.S115061 |
work_keys_str_mv | AT unfriedklaus reductionofneutrophiliclunginflammationbyinhalationofthecompatiblesoluteectoinearandomizedtrialwithelderlyindividuals AT kramerursula reductionofneutrophiliclunginflammationbyinhalationofthecompatiblesoluteectoinearandomizedtrialwithelderlyindividuals AT sydlikulrich reductionofneutrophiliclunginflammationbyinhalationofthecompatiblesoluteectoinearandomizedtrialwithelderlyindividuals AT autengruberandrea reductionofneutrophiliclunginflammationbyinhalationofthecompatiblesoluteectoinearandomizedtrialwithelderlyindividuals AT bilsteinandreas reductionofneutrophiliclunginflammationbyinhalationofthecompatiblesoluteectoinearandomizedtrialwithelderlyindividuals AT stolzsabine reductionofneutrophiliclunginflammationbyinhalationofthecompatiblesoluteectoinearandomizedtrialwithelderlyindividuals AT marinialessandra reductionofneutrophiliclunginflammationbyinhalationofthecompatiblesoluteectoinearandomizedtrialwithelderlyindividuals AT schikowskitamara reductionofneutrophiliclunginflammationbyinhalationofthecompatiblesoluteectoinearandomizedtrialwithelderlyindividuals AT keymelstefanie reductionofneutrophiliclunginflammationbyinhalationofthecompatiblesoluteectoinearandomizedtrialwithelderlyindividuals AT krutmannjean reductionofneutrophiliclunginflammationbyinhalationofthecompatiblesoluteectoinearandomizedtrialwithelderlyindividuals |